Italy’s Menarini Diagnostics is to distribute the EpiCheck non-invasive bladder cancer urine test from Israel’s Nucleix (see here previously) in Europe. Bladder cancer is the sixth most common cancer as there are approximately 760,000 people in Europe with the disease. … Continue reading →

I reported previously (Jun 2014) on the non-invasive urine test of Israel’s Nucleix for monitoring bladder cancer treatment. Following a multi-center, 400-patients clinical trial, Nucleix has received the CE Mark allowing it to market Bladder EpiCheck in the E.U. https://www.israel21c.org/bladder-cancer-monitor-gets-ce-mark-lung-cancer-test-next/